Today: 8 May 2026
Standard Chartered share price ticks higher as Feb. 24 earnings and dividend call come into focus
6 February 2026
1 min read

Standard Chartered share price ticks higher as Feb. 24 earnings and dividend call come into focus

London, Feb 6, 2026, 09:36 GMT — Regular session

  • Standard Chartered shares edged higher in early London trading, with investors gearing up for the Feb. 24 earnings report and dividend announcement.
  • Before the full-year results, JPMorgan raised its price target for the shares.
  • Traders are focused on whether the bank can follow its strong stock rally with solid 2025 results and clear signals on capital returns.

Shares of Standard Chartered (STAN.L) edged up 0.5% to roughly 1,857 pence by 0936 GMT on Friday, after an early spike pushed the price to 1,876.5 pence. The stock had closed at 1,847 pence on Thursday and is now up about 72% in the past year, according to data from Hargreaves Lansdown.

The bank signaled its next major date for investors. In a regulatory filing linked to its Hong Kong listing, Standard Chartered revealed that a board committee will convene on Feb. 24 to approve the results for the year ending Dec. 31, 2025, and to decide on a final dividend. The announcement noted it would be “considering the payment of a final dividend, if any.” Investegate

Feb. 24 is the next key date for a stock that’s already surged into 2026. Standard Chartered plans to release its full-year results at 04:00 UK time, followed by a virtual presentation with CEO Bill Winters and CFO Diego De Giorgi at 08:00 UK time.

Broker sentiment gave shares a boost. JPMorgan’s Kian Abouhossein lifted his price target to 2,170 pence from 1,880, maintaining an “Overweight” rating that suggests he sees the stock outpacing its rivals. TipRanks

On Wednesday, a regulatory update clarified the share count. Standard Chartered reported having 2,253,842,687 shares in issue as of Jan. 31, matching the number of voting rights and with no shares held in treasury. Investors rely on these figures to monitor disclosure thresholds and assess the impact of buybacks.

Banking stocks showed a mixed picture. European shares in the sector fell 3.5% Thursday as investors processed uneven earnings reports. The European Central Bank held rates steady at 2%. BBVA shares slumped 8.8% post-results, but BNP Paribas edged up 1.2%.

Standard Chartered stands somewhat apart from other UK banks, focusing on corporate and investment banking, wealth management, retail, and a smaller ventures division. Its operations are heavily linked to cross-border trade and investment flows.

Investors will zero in on guidance around income growth, costs, and shareholder returns when the company reports on Feb. 24. Loan-loss provisions — cash reserved for potential bad loans — could also move the needle, particularly if management highlights any areas of concern.

Dividend decisions aren’t guaranteed. A weak earnings report or a cautious forecast could send shares tumbling fast. If risk appetite sours sharply, or credit losses start to rise, it would challenge the notion that the bank can keep handing out cash while also funding growth.

Next up on the calendar: Standard Chartered’s 2025 results drop at 04:00 UK time on Feb. 24. Management will face investors just a few hours after that.

Stock Market Today

  • Odyssey Therapeutics Raises $304M in Nasdaq IPO to Advance Autoimmune Pipeline
    May 8, 2026, 7:56 AM EDT. Odyssey Therapeutics completed a $304 million initial public offering (IPO) on Nasdaq, targeting autoimmune and inflammatory diseases. The biotech issued 15.5 million shares at $18 each, exceeding earlier share estimates and raising funds above initial projections. Proceeds will primarily support clinical trials of lead drug OD-001, a RIPK2 inhibitor for ulcerative colitis, with $135 million allocated to phase 2 studies. Another $50 million is earmarked for advancing a preclinical SLC15A4 program into early-stage trials targeting lupus and B cell-mediated autoimmune disorders. Led by Gary Glick, Odyssey has secured $726.5 million in funding since 2021, including recent significant venture rounds backed by OrbiMed. The IPO proceeds strengthen Odyssey's pipeline development amid heightened investor interest in autoimmune therapies.

Latest article

Tempus AI Just Priced a $400 Million Debt Deal. Here’s What Investors Need to Watch

Tempus AI Just Priced a $400 Million Debt Deal. Here’s What Investors Need to Watch

8 May 2026
Tempus AI priced a $400 million private sale of 0% convertible senior notes due 2032, upsized from $350 million, to repay $307.7 million in loans and fund operations. The deal follows first-quarter revenue of $348.1 million, up 36%, but a net loss widened to $125.9 million. Shares traded at $49.47 premarket, down $4.07. The notes convert at $69.26 per share, a 40% premium to the last close.
Zoetis Stock Plunge: The Pet-Care Slowdown Wall Street Can’t Ignore

Zoetis Stock Plunge: The Pet-Care Slowdown Wall Street Can’t Ignore

8 May 2026
Zoetis cut its 2026 revenue forecast to $9.68 billion-$9.96 billion and lowered adjusted EPS guidance after U.S. companion-animal product sales dropped 11% in the first quarter. Shares fell $23.86 to $87.31. First-quarter adjusted EPS came in at $1.53, missing analyst estimates of $1.61. CEO Kristin Peck cited weaker demand, fewer vet visits, and increased competition.
Gas Prices May Stay High Even After an Iran Peace Deal — Here’s Why

Gas Prices May Stay High Even After an Iran Peace Deal — Here’s Why

8 May 2026
U.S. regular gasoline averaged $4.546 a gallon Friday, near its highest since 2022, according to AAA. Prices remain elevated as fighting near the Strait of Hormuz disrupts oil flows, despite signs of progress toward a U.S.-Iran deal. Analysts say pump prices are unlikely to return to pre-war levels before 2027. Oil benchmarks hovered near $100 a barrel, with inventories still low.
Barclays share price rebounds as BoE rate-cut bets swirl; results due Feb 10
Previous Story

Barclays share price rebounds as BoE rate-cut bets swirl; results due Feb 10

Amazon stock drops in premarket as $200 billion AI capex plan grabs the spotlight
Next Story

Amazon stock drops in premarket as $200 billion AI capex plan grabs the spotlight

Go toTop